|
|
 |
|
Viewing report
|
|
|
|
Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market
GBI Research, April 2011, Pages: 108
Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market
Summary
GBI Research has released its pharmaceutical research, “Gout Therapeutics Market to 2017 - Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market”, which provides insights into gout therapeutics sales and price forecasts until 2017. The report also delves deep into global gout treatment usage patterns. Furthermore, the geographical distribution of the gout therapeutics market across key geographies (the US, the top five countries of Europe, and Japan) is also provided in the report. The report also provides insights into the gout therapeutics R&D pipeline and the promising future blockbusters by 2017. The report provides an in-depth analysis of acute and chronic gout. Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also covers the profiles of major biopharmaceutical companies in this therapeutics segment. Finally, analysis of mergers and acquisitions, and licensing agreements involving gout therapeutics, is also provided.
GBI Research analysis showed that the global gout therapeutics market was estimated at $542.6m in 2010, with a year-on-year growth rate of 7% between 2002 and 2010. The gout therapeutics market is expected to shift towards biologics that are more efficient and safe compared to conventional therapies. GBI Research forecasts the market to grow at a Compound Annual Growth Rate (CAGR) of approximately 16.3% between 2010 and 2017, to record a sales value of approximately $1,561.3m. The gout therapeutics market had only generics until the launch of Colcrys (colchicine) and TMX 67 (febuxostat) in 2009 and 2010 respectively. In-depth analysis of the report is based on proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of experts.
Scope
The report covers -
- Data and analysis on the gout therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the gout therapeutics market from 2002 to 2010, with forecasts to 2017.
- In-depth analysis of the acute and chronic gout therapeutics market.
- Market data on geographical landscape and therapeutic landscape including market size, annual cost of therapy, revenues and treatment usage patterns such as diseased population, treatment seeking population, diagnosed population and prescription population.
- Key drivers and barriers that have created a significant impact on the market.
- Profiles of the major biopharmaceutical markets in the gout therapeutics segment. The key companies studied in this report are Takeda Pharmaceutical Company, Savient Pharmaceuticals, Novartis, Regeneron Pharmaceuticals and Teijin Pharma.
- Key M&A activities and Licensing Agreements, that have taken place between 2004 and 2010 in the gout therapeutics market.
Reasons to buy
The report will aid business development and marketing executives strategizing their product launches -
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
|
|
|
|
